MTF Biologics’ Post

Did you know that NHS Trusts throughout the UK are struggling to cope with the demands of patient care and management for conditions in Haematology and Oncology? 🔎 By employing an innovative new model approach, Apodi sought to gather Deep Insight into the services and solutions that would improve patient access to medicines within specific treatment areas. 🚀 To discover how Apodi addressed the specific needs, as well as challenges, present in the Haematology and Oncology fields, click here 👉 https://lnkd.in/dHzB6egn

🌟 𝗡𝗲𝘄 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝗔𝗹𝗲𝗿𝘁: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗜 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟   FDA Approval of Tucatinib and Trastuzumab for Refractory HER+ WT mCRC: Insights from the MOUNTAINEER-02 trial Shared by Prof Eric Van Cutsem and Prof Van den Eynde.   👇 Watch all WND GI videos - link in the comments! #MediMix #GastricCancer #Immunotherapy #OncologyResearch

BYOT: It’s a #hot topic. And a dream for many of us. Join us to hear Noelle Gaskill, MBA, ACRP-CP share how she made this dream a reality. Let’s ask all the questions so we can scale her approach! #dct #bringyourowntech #oncology #interoperability

Visit the #AACRBlog to learn about the history of tumor-infiltrating lymphocyte (TIL) therapy—from the discovery of TILs in 1986 to its historic FDA approval earlier this year—and where new research is headed. https://bit.ly/4aJAnen #MelanomaAwarenessMonth

Alligator Bioscience AB announced positive top-line results from the OPTIMIZE-1 Phase II trial in pancreatic cancer, revealing that #mitazalimab combined with #mFOLFIRINOX achieved a 40.4% overall response rate (ORR), a median duration of response (DoR) of 12.5 months, and a median overall survival (mOS) of 14.3 months. This compares favorably to the 11.1 months mOS seen with first-line chemotherapies #FOLFIRINOX and #NALIFIROX. With more than half of the patients still in the study at the primary analysis, the 18-month survival follow-up data was presented at ASCO 2024. Get Ahead with Expert Insights and Full Analysis through DelveInsight Business Research LLP's Exclusive American Society of Clinical Oncology (ASCO) 2024 Coverage: https://lnkd.in/gvjRd-zM #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

Did you miss our webinar on 'The Ongoing Expansion of Subcutaneous Anti-Cancer Therapies (SACT) supported by Roche? The full webinar is now available on our YouTube channel. 📺 Watch it here: https://lnkd.in/guVxfBR2

RELAX CRITERIA - EXPAND REACH FDA issues three draft guidances to expand cancer clinical trial eligibility. The documents address the areas of: laboratory values, washout periods & concomitant medicines, and patient’s performance status The guidance aims to promote greater participation and diversity by expanding eligibility criteria. #PatientEligibility #access #outreach #diversity #clinicaltrials #oncology #fda #InclusionCriteria #cancer #CureCancer

The Theranojet®ARA is a shielded injection system developed by Lemer Pax for the safe and precise administration of radiopharmaceuticals in theranostic applications. It features advanced radiation protection, ease of use, and secure patient administration. Key Features: 1. Radiation Protection: The system employs lead and lead glass shielding to minimize radiation exposure to medical personnel during preparation, administration, and disposal of radiopharmaceuticals . 2. Ease of Use: With its mobile design, removable drip tray, and contamination tray, the Theranojet®ARA is easy to maneuver and clean . 3. Patient Safety: The configurable pump detects occlusions and air bubbles, preventing extravasation and ensuring safe injection . 4. Successful Implementation: Used effectively at the Beaujon AP-HP Hospital in Paris for Lutetium-177 therapies, the system significantly reduces radiation exposure for healthcare staff . Importance of Minimizing Contamination and Residuals: Injecting a therapeutic radioactive material like Lutetium-177, which has a long half-life, without contamination and minimal residuals is crucial for several reasons: 1. Safety of Medical Personnel: Reducing contamination prevents unnecessary radiation exposure to healthcare workers, which is essential for maintaining their safety and health . 2. Patient Safety: Ensuring no residuals or contamination minimizes the risk of unintended radiation doses to patients, which can lead to complications or ineffective treatment. 3. Environmental Safety: Proper handling and disposal of radioactive materials prevent environmental contamination, protecting the broader community and ecosystem. 4. Therapeutic Efficacy: Accurate dosing without residuals ensures that the patient receives the correct therapeutic dose, optimizing treatment effectiveness for conditions like metastatic neuroendocrine tumors and prostate cancer . The Theranojet®ARA’s design addresses these concerns by providing a safe, efficient, and contamination-free method for administering radiopharmaceuticals, making it a vital tool in modern nuclear medicine.

The US FDA Approves AstraZeneca’s Tagrisso, in Combination with Chemotherapy, for Treating EGFRm Advanced NSCLC #astrazeneca #tagrisso #nonsmallcelllungcancer #regulatory #approval #usfda #nsclc #chemotherapy #phase3 #flaura2 #priorityreview #combinationtherapy #monotherapy #egfrmnsclc #pfs #centralnervoussystem

FDA Grants Orphan Drug Designation for Avutometinib Alone or With Defactinib in Recurrent LGSOC: The designation is for all patients with low-grade serous ovarian cancer, regardless of their KRAS status and after 1 or more prior lines of therapy. #finance #pharmacy #lifesciences